Moreover, such procedures may prove more helpful than other options among people who suffer from obesity or related complications
A 52-week treatment with tirzepatide (5mg, 10mg, or 15 mg) led to a significant MASH resolution without worsening liver fibrosis compared to placebo (Fig.3)
While GLP-1 medications are not a 'quick fix,' they can be a powerful tool for regaining momentum, reducing health risks, and supporting long-term weight management goals
These effects are typically most pronounced during dose initiation and escalation, generally improving over time as physiological adaptation occurs
MOTS-C dosing stays the same regardless
For example, a patient who struggles with constant hunger may benefit most from a GLP-1 therapy, while someone who eats primarily in response to stress or emotion may respond better to a medication that targets neurological reward pathways